CA2825309C - Pyridostigmine for the treatment of obstructive sleep apnea - Google Patents
Pyridostigmine for the treatment of obstructive sleep apnea Download PDFInfo
- Publication number
- CA2825309C CA2825309C CA2825309A CA2825309A CA2825309C CA 2825309 C CA2825309 C CA 2825309C CA 2825309 A CA2825309 A CA 2825309A CA 2825309 A CA2825309 A CA 2825309A CA 2825309 C CA2825309 C CA 2825309C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- sleep
- pyridostigmine
- subject
- osa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000001797 obstructive sleep apnea Diseases 0.000 title claims abstract description 102
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 title claims abstract description 92
- 229960002290 pyridostigmine Drugs 0.000 title claims abstract description 92
- 238000011282 treatment Methods 0.000 title claims description 40
- 230000007958 sleep Effects 0.000 claims abstract description 71
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 46
- 206010041235 Snoring Diseases 0.000 claims abstract description 42
- 208000008784 apnea Diseases 0.000 claims description 44
- 210000002966 serum Anatomy 0.000 claims description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 19
- 230000003860 sleep quality Effects 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 239000001301 oxygen Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 14
- 239000003085 diluting agent Substances 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 238000013270 controlled release Methods 0.000 claims description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 230000001387 anti-histamine Effects 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 239000006186 oral dosage form Substances 0.000 claims description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 55
- 238000000034 method Methods 0.000 abstract description 36
- 208000024891 symptom Diseases 0.000 abstract description 17
- 206010021079 Hypopnoea Diseases 0.000 description 41
- 230000009467 reduction Effects 0.000 description 27
- 229940079593 drug Drugs 0.000 description 26
- 206010041349 Somnolence Diseases 0.000 description 17
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 15
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 12
- 230000037007 arousal Effects 0.000 description 12
- 239000000902 placebo Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000029058 respiratory gaseous exchange Effects 0.000 description 10
- 230000000241 respiratory effect Effects 0.000 description 8
- 230000004622 sleep time Effects 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- 206010062519 Poor quality sleep Diseases 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000000044 Amnesia Diseases 0.000 description 5
- 206010019280 Heart failures Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 231100000863 loss of memory Toxicity 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- 208000002815 pulmonary hypertension Diseases 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 4
- 208000016097 disease of metabolism Diseases 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000000414 obstructive effect Effects 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 201000002859 sleep apnea Diseases 0.000 description 3
- 208000037905 systemic hypertension Diseases 0.000 description 3
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000007681 bariatric surgery Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007887 hard shell capsule Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 150000002926 oxygen Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010006322 Breath holding Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 206010008589 Choking Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- VNYBTNPBYXSMOO-UHFFFAOYSA-M Pyridostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=C[N+](C)=C1 VNYBTNPBYXSMOO-UHFFFAOYSA-M 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000008933 bodily movement Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960002516 physostigmine salicylate Drugs 0.000 description 1
- HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960002151 pyridostigmine bromide Drugs 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices ; Anti-rape devices
- A61F5/56—Devices for preventing snoring
- A61F5/566—Intra-oral devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0057—Pumps therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Nursing (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437272P | 2011-01-28 | 2011-01-28 | |
| US61/437,272 | 2011-01-28 | ||
| PCT/US2012/022825 WO2012103398A2 (en) | 2011-01-28 | 2012-01-27 | Methods for treating obstructive sleep apnea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2825309A1 CA2825309A1 (en) | 2012-08-02 |
| CA2825309C true CA2825309C (en) | 2019-10-01 |
Family
ID=46577943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2825309A Active CA2825309C (en) | 2011-01-28 | 2012-01-27 | Pyridostigmine for the treatment of obstructive sleep apnea |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8753327B2 (Direct) |
| EP (1) | EP2672972B1 (Direct) |
| JP (2) | JP2014503593A (Direct) |
| CN (2) | CN107007602A (Direct) |
| CA (1) | CA2825309C (Direct) |
| WO (1) | WO2012103398A2 (Direct) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012103398A2 (en) * | 2011-01-28 | 2012-08-02 | Jian-Qiang Fan | Methods for treating obstructive sleep apnea |
| JP2017506929A (ja) * | 2014-03-03 | 2017-03-16 | スリープ イノベイションズ プロプライアタリー リミティド | 睡眠時無呼吸治療の装置及び方法 |
| WO2016014229A1 (en) * | 2014-07-25 | 2016-01-28 | Mendelowitz David | Oxytocin improves treatment of obstructive sleep apnea |
| EP3552649B1 (en) | 2015-04-02 | 2023-08-23 | Hill-Rom Services PTE. LTD. | Pressure control of respiratory device |
| WO2018115351A1 (en) * | 2016-12-23 | 2018-06-28 | Koninklijke Philips N.V. | System for treating snoring among at least two users |
| KR20240042261A (ko) * | 2017-04-28 | 2024-04-01 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 수면 무호흡을 치료하기 위한 방법 및 조성물 |
| DK3746126T3 (da) | 2018-01-30 | 2024-10-07 | Apnimed Inc Delaware | Fremgangsmåder og sammensætninger til behandling af søvnapnø eller simpel snorken |
| CA3061382C (en) * | 2018-06-18 | 2020-12-15 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
| CN112601568B (zh) * | 2018-08-24 | 2024-07-26 | 皇家飞利浦有限公司 | 利用压力治疗系统提供睡眠治疗 |
| US11654283B2 (en) | 2019-03-06 | 2023-05-23 | Medtronic Xomed, Inc. | Obstructive sleep apnea patient programmer for implantable devices |
| CN114504643B (zh) * | 2021-12-24 | 2024-03-26 | 北京大学第一医院 | 抗IgE抗体在用于治疗OSAS中的应用 |
| CN120390613A (zh) * | 2022-12-28 | 2025-07-29 | 西川株式会社 | 健康风险判定系统、自律神经判定系统、生活改善系统、睡姿判定系统、睡姿判定程序、磨牙检测系统及磨牙检测程序 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2247662B (en) | 1990-08-31 | 1994-11-02 | Instance Ltd David J | Labels and manufacture thereof |
| SE9504537D0 (sv) * | 1995-12-19 | 1995-12-19 | Jan Hedner | Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet |
| CA2535613A1 (en) * | 2003-08-13 | 2005-02-24 | Janssen Pharmaceutica, N.V. | Treatment of sleep disorders with cholinesterase inhibitors |
| WO2007032720A1 (en) * | 2005-09-16 | 2007-03-22 | Cereuscience Ab | Method and means of preventing and treating sleep disordered breathing |
| US20080066739A1 (en) * | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| US7984714B2 (en) * | 2006-09-29 | 2011-07-26 | Nellcor Puritan Bennett Llc | Managing obstructive sleep apnea and/or snoring using local time released agents |
| WO2012103398A2 (en) * | 2011-01-28 | 2012-08-02 | Jian-Qiang Fan | Methods for treating obstructive sleep apnea |
-
2012
- 2012-01-27 WO PCT/US2012/022825 patent/WO2012103398A2/en not_active Ceased
- 2012-01-27 CA CA2825309A patent/CA2825309C/en active Active
- 2012-01-27 EP EP12739245.4A patent/EP2672972B1/en active Active
- 2012-01-27 CN CN201610821591.8A patent/CN107007602A/zh active Pending
- 2012-01-27 JP JP2013551354A patent/JP2014503593A/ja active Pending
- 2012-01-27 CN CN2012800065522A patent/CN103458899A/zh active Pending
- 2012-01-27 US US13/359,692 patent/US8753327B2/en active Active
-
2014
- 2014-05-05 US US14/269,326 patent/US9295670B2/en active Active
-
2017
- 2017-01-04 JP JP2017000145A patent/JP6342525B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107007602A (zh) | 2017-08-04 |
| JP2017095485A (ja) | 2017-06-01 |
| CA2825309A1 (en) | 2012-08-02 |
| EP2672972B1 (en) | 2020-11-04 |
| JP6342525B2 (ja) | 2018-06-13 |
| WO2012103398A2 (en) | 2012-08-02 |
| US20140238412A1 (en) | 2014-08-28 |
| US20120197235A1 (en) | 2012-08-02 |
| EP2672972A2 (en) | 2013-12-18 |
| US9295670B2 (en) | 2016-03-29 |
| US8753327B2 (en) | 2014-06-17 |
| CN103458899A (zh) | 2013-12-18 |
| EP2672972A4 (en) | 2014-09-10 |
| WO2012103398A9 (en) | 2012-09-27 |
| JP2014503593A (ja) | 2014-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2825309C (en) | Pyridostigmine for the treatment of obstructive sleep apnea | |
| CN110799181A (zh) | 用于治疗睡眠呼吸暂停的方法和组合物 | |
| AU2003301824B2 (en) | Use of serotonin receptor antagonists for the treatment of sleep apnea | |
| JP5712452B2 (ja) | 診断された呼吸疾患を有する患者もしくは診断未確定の呼吸疾患を有する患者におけるオピオイド鎮痛薬の投与に関連する危険性を減少するための方法および組成 | |
| JP7705348B2 (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| CN100558358C (zh) | 唑尼沙胺在制备用于治疗或预防阻塞性睡眠呼吸暂停的药物中的应用 | |
| CN1278731A (zh) | 米氮平用于治疗睡眠性呼吸暂停的用途 | |
| HK1241728A1 (en) | Methods for treating obstructive sleep apnea | |
| TW200528098A (en) | Treatment of insomnia in human patients | |
| McNicholas | Sleep in chronic obstructive pulmonary | |
| Pillar et al. | Amelioration of Sleep Apnea by Salicylate-induced Hyperventilation1, 2 | |
| Calianese et al. | Atomoxetine plus oxybutynin for symptomatic snoring and airflow limitation in individuals without moderate-to-severe obstructive sleep apnea | |
| KR20250000641A (ko) | 수면장애 및/또는 수면장애 관련 질환을 예방, 개선 또는 치료하는 방법 | |
| HK40109449A (zh) | 慢性咳嗽、呼吸急促和呼吸困难的治疗 | |
| HK40109451A (zh) | 慢性咳嗽、呼吸急促和呼吸困难的治疗 | |
| HK40109450A (zh) | 慢性咳嗽、呼吸急促和呼吸困难的治疗 | |
| HK40109448A (zh) | 慢性咳嗽、呼吸急促和呼吸困难的治疗 | |
| Dobbin et al. | Obstructive sleep apnea: recognition and management considerations for the aged patient | |
| WO2025111597A1 (en) | A treatment for patients with mood disorders using n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine or a pharmaceutically acceptable salt thereof | |
| Palmer et al. | Medical disorders | |
| HK40045293B (zh) | 慢性咳嗽、呼吸急促和呼吸困难的治疗 | |
| Milani | Levocloperastine: A Review on pharmacodynamics, clinical efficacy, tolerability and safety in the treatment of chronic cough | |
| Trounce | Drugs in Current Use | |
| FARIDI et al. | Postoperative analgesia: a comparison of sublingual buprenorphine and intramuscular morphine for pain relief after abdominal hysterectomy | |
| CZ300781B6 (cs) | Použití R-(+)-alfa-(2,3-dimethoxyfenyl)-1-[2-(4-fluorfenyl)ethyl]-4-piperidinmethanolu pro lécení poruch spánku |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170124 |